Developer docs
API playgroundTry for free, no card

Search company profiles

Envue Technologies

Full company profile

uuid0006ahu

Namestring
Envue Technologies
Legal namestring
Envue Technologies
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Envue Technologies is a Swedish biotech instrumentation company, founded as a spinout from the Langhammer group at Chalmers University of Technology and headquartered at Stena Center, Läraregatan 3, Gothenburg. The company develops and commercializes a label-free optical microscopy platform called Nanofluidic Scattering Microscopy (NSM), which combines cleanroom-fabricated nanofluidic chips, a custom-built dark-field optical microscope, and a proprietary data analysis pipeline (combining machine learning with conventional algorithms) to image and characterize freely moving single biomolecules — down to tens of kDa — in real time without fluorescent labels. The NSM method and its ability to simultaneously determine mass and size of individual nanoscale objects were published in Nature Methods in May 2022, anchoring Envue's scientific credibility.

Envue monetizes the NSM platform through two product lines — the modular Custom Instrument (a research-grade microscope-plus-chips-plus-software system) and the EnvueR One all-in-one benchtop instrument — and complements hardware sales with a paid Sample Analysis Service, where customers submit sample details and receive a quoted timeframe and price. Distribution is direct (no resellers or marketplace listings) with CTAs for demo and sample analysis, and the company targets biopharma/drug-discovery research (nucleic acid and protein therapeutics, molecular interactions, oligomer QC) as well as academic and analytical QC labs. Capitalization was predominantly non-dilutive — Swedish and EU grants from Vinnova (~900,000 SEK), the ÅForsk Foundation (200,000 SEK scholarship to the CEO), and the EIC WomenTechEU programme (€75,000) — supplemented by a small Chalmers Ventures commitment. In November 2025, Envue was acquired by NanoTemper Technologies GmbH (Munich), with the NSM technology integrated into NanoTemper's biophysical analysis portfolio alongside the launch of the Dianthus α application for drug discovery.

Short descriptiontext

Envue Technologies is a Swedish biotech instrumentation spinout from Chalmers University of Technology that develops Nanofluidic Scattering Microscopy (NSM), a label-free optical platform for real-time mass and size characterization of single biomolecules, sold to biopharma and academic research labs via the Custom Instrument, EnvueR One, and a paid Sample Analysis Service.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGöteborg, Sweden
HQ citystring
Göteborg
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
label-free optical microscopy, biomolecule characterization instruments, nanofluidic scattering microscopy, biophysical analysis tools, nanoparticle characterization systems
Industry1 code
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Biophysical Analysis Instruments
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Instrument Sales
TypeHardware Sales
Description

Sale of the Custom Instrument and EnvueR One scientific instruments — next-generation instruments for characterizing objects in the nanoworld. Capital equipment sales model targeting biopharma and academic research labs.

envue-technologies.com
2Sample Analysis Services
TypeProfessional Services
Description

Paid sample analysis service — customers submit samples and Envue returns a suggested timeframe and a quote. Likely a land-and-expand motion converting service customers into instrument purchasers.

envue-technologies.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Pricing details1 tier
1Quote-based analysis service and instrument pricing — not publicly disclosed
ModelOther
Notes

Customers submit a request form with sample size, concentration, buffer and timeframe; Envue returns a suggested timeframe and a quote. No public price list, tiers, or pricing model disclosed for the Custom Instrument or EnvueR One.

envue-technologies.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Envue Technologies develops, manufactures, and commercializes scientific instruments based on its proprietary Nanofluidic Scattering Microscopy (NSM) platform for the label-free characterization of biomolecules and nanoparticles. The company sells a modular Custom Instrument, an all-in-one EnvueR One benchtop instrument, and bundled nanofluidic chips with proprietary data analysis software, alongside fee-based sample analysis services for drug discovery and academic research customers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Envue Technologies offers a single unified scientific-instrument platform built around its proprietary Nanofluidic Scattering Microscopy (NSM) method, delivered through two hardware product lines — The Custom Instrument (a modular microscope-plus-chips-plus-software system for research users) and The EnvueR One (an all-in-one benchtop instrument for routine mass and size measurements). Both products share the same three core technology elements: a cleanroom-fabricated nanofluidic chip, a specially designed dark-field optical microscope, and proprietary data-analysis software that combines machine learning with conventional algorithms. In November 2025, Envue was acquired by NanoTemper Technologies GmbH, integrating NSM into a broader biopharma drug-discovery portfolio alongside the newly launched Dianthus α application. Envue also monetizes the underlying capability directly via a Sample Analysis Service for customers who do not yet own an instrument.

Product and service1 record
1The Custom Instrument
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

NanoTemper Technologies GmbH announced the acquisition of Swedish startup Envue Technologies and the launch of its Dianthus α application on 2025-11-05/06. The acquisition integrates Envue's Nanofluidic Scattering Microscopy (NSM) technology into NanoTemper's biophysical analysis portfolio for drug discovery.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-09-28
Description

Envue selected to participate in REACH, a Silicon Valley-based incubator program designed to boost Nordic research-based tech projects and spin-outs with international ambitions. Program spans a year including a two-week trip to Silicon Valley in March 2023.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Envue was started as a spinout company from the Langhammer group at Chalmers University of Technology. The NSM method was developed by combining expertise in nano fabrication, nano optics and biophysics at Chalmers.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Analytical instrument and biocolumns vendor (SEC, CE, mass spec) serving biopharma characterization workflows. Comparable because it competes for analytical budget around protein and nucleic acid characterization in discovery and QC.

TypeBroad incumbent
Description

Supplies bioprocess and analytical tools (ÄKTA, MicroCal ITC/DSF) used across biopharma discovery, developability, and QC. Comparable because it sells complementary label-free characterization workflows to the same biopharma buyer.

TypeBroad incumbent
Description

Established label-free particle-sizing incumbent via Zetasizer (DLS) and NanoSight (NTA). Comparable because these are the primary alternative label-free techniques that NSM positions against for biomolecule and nanoparticle characterization.

TypeEmerging player
Description

Developer of microfluidic label-free tools (Fluidity One) for protein interaction and sizing measurements. Comparable as a smaller player using microfluidics to deliver label-free biomolecule characterization in similar customer segments.

TypeEmerging player
Description

Sells benchtop biophysical tools for biologics developability (e.g., Uncle, Hunky, LUNATIC). Comparable because it targets the same biologics-formulation and developability workflows that NSM's mass/size and aggregation use cases address.

6Wyatt Technology
TypeBroad incumbent
Description

Provides SEC-MALS, DLS (DynaPro), and field-flow fractionation for absolute molecular weight and size of biomolecules. Comparable because it competes for the same protein, nucleic acid, and aggregate characterization budgets in biopharma R&D and QC.

TypeDirect peer
Description

Refeyn commercializes mass photometry, the most established label-free single-molecule mass measurement technique. It is the closest direct competitor to Envue's NSM, serving the same biopharma discovery and academic customers with overlapping value propositions.

TypeBroad incumbent
Description

Largest life-sciences tools vendor with mass spectrometry, microcalorimetry, and chromatography for protein characterization. Comparable as the broadest incumbent that could compete with or absorb NSM-style capabilities over time.

TypeOthers
Description

Acquirer of Envue and broader biophysical analysis incumbent offering DSF (Prometheus), MST, and now Dianthus α/NSM. Comparable because it sells to the same drug-discovery customers and increasingly bundles NSM into its portfolio.

TypeBroad incumbent
Description

Large analytical instrument vendor with mass spectrometry, AFM, and biophysical tools relevant to protein characterization. Comparable as a broad incumbent with the ability to bundle orthogonal label-free techniques alongside NSM-type offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Envue Technologies

Biophysical Analysis Instrumentsenvue-technologies.com

Envue Technologies is a Swedish biotech instrumentation spinout from Chalmers University of Technology that develops Nanofluidic Scattering Microscopy (NSM), a label-free optical platform for real-time mass and size characterization of single biomolecules, sold to biopharma and academic research labs via the Custom Instrument, EnvueR One, and a paid Sample Analysis Service.

What Envue Technologies does

Envue Technologies is a Swedish biotech instrumentation company, founded as a spinout from the Langhammer group at Chalmers University of Technology and headquartered at Stena Center, Läraregatan 3, Gothenburg. The company develops and commercializes a label-free optical microscopy platform called Nanofluidic Scattering Microscopy (NSM), which combines cleanroom-fabricated nanofluidic chips, a custom-built dark-field optical microscope, and a proprietary data analysis pipeline (combining machine learning with conventional algorithms) to image and characterize freely moving single biomolecules — down to tens of kDa — in real time without fluorescent labels. The NSM method and its ability to simultaneously determine mass and size of individual nanoscale objects were published in Nature Methods in May 2022, anchoring Envue's scientific credibility.

Envue monetizes the NSM platform through two product lines — the modular Custom Instrument (a research-grade microscope-plus-chips-plus-software system) and the EnvueR One all-in-one benchtop instrument — and complements hardware sales with a paid Sample Analysis Service, where customers submit sample details and receive a quoted timeframe and price. Distribution is direct (no resellers or marketplace listings) with CTAs for demo and sample analysis, and the company targets biopharma/drug-discovery research (nucleic acid and protein therapeutics, molecular interactions, oligomer QC) as well as academic and analytical QC labs. Capitalization was predominantly non-dilutive — Swedish and EU grants from Vinnova (~900,000 SEK), the ÅForsk Foundation (200,000 SEK scholarship to the CEO), and the EIC WomenTechEU programme (€75,000) — supplemented by a small Chalmers Ventures commitment. In November 2025, Envue was acquired by NanoTemper Technologies GmbH (Munich), with the NSM technology integrated into NanoTemper's biophysical analysis portfolio alongside the launch of the Dianthus α application for drug discovery.

Envue Technologies firmographics

Firmographics
Name
Envue Technologies
Legal name
Envue Technologies
Website
https://envue-technologies.com
Company type
Private
Founded year
2022
Operating status
Acquired
Headcount range
1–10 employees
Short description
Envue Technologies is a Swedish biotech instrumentation spinout from Chalmers University of Technology that develops Nanofluidic Scattering Microscopy (NSM), a label-free optical platform for real-time mass and size characterization of single biomolecules, sold to biopharma and academic research labs via the Custom Instrument, EnvueR One, and a paid Sample Analysis Service.
Ownership category
akta.pro rank

Envue Technologies industry classification

Industry
Product category
Biophysical Analysis Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments

Keywords

  • Label-free optical microscopy
  • Biomolecule characterization instruments
  • Nanofluidic scattering microscopy
  • Biophysical analysis tools
  • Nanoparticle characterization systems

Where Envue Technologies is headquartered

Location

Headquarters

HQ city
Göteborg
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Envue Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Instrument Sales: Sale of the Custom Instrument and EnvueR One scientific instruments — next-generation instruments for characterizing objects in the nanoworld. Capital equipment sales model targeting biopharma and academic research labs.
  2. Sample Analysis Services: Paid sample analysis service — customers submit samples and Envue returns a suggested timeframe and a quote. Likely a land-and-expand motion converting service customers into instrument purchasers.

Pricing tiers

ModelBillingPrice
Other—Quote-based analysis service and instrument pricing — not publicly disclosed

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Envue Technologies product offering

Product offering

Core offering

Envue Technologies develops, manufactures, and commercializes scientific instruments based on its proprietary Nanofluidic Scattering Microscopy (NSM) platform for the label-free characterization of biomolecules and nanoparticles. The company sells a modular Custom Instrument, an all-in-one EnvueR One benchtop instrument, and bundled nanofluidic chips with proprietary data analysis software, alongside fee-based sample analysis services for drug discovery and academic research customers.

Product overview

Envue Technologies offers a single unified scientific-instrument platform built around its proprietary Nanofluidic Scattering Microscopy (NSM) method, delivered through two hardware product lines — The Custom Instrument (a modular microscope-plus-chips-plus-software system for research users) and The EnvueR One (an all-in-one benchtop instrument for routine mass and size measurements). Both products share the same three core technology elements: a cleanroom-fabricated nanofluidic chip, a specially designed dark-field optical microscope, and proprietary data-analysis software that combines machine learning with conventional algorithms. In November 2025, Envue was acquired by NanoTemper Technologies GmbH, integrating NSM into a broader biopharma drug-discovery portfolio alongside the newly launched Dianthus α application. Envue also monetizes the underlying capability directly via a Sample Analysis Service for customers who do not yet own an instrument.

Differentiator

Problem solved

Functional benefit

Products and services

  • The Custom Instrument

Companies that use Envue Technologies

Customer profile

Segments3 records

Ideal customer profiles2 records

Envue Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Envue Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship, minor and core.

  • NanoTemper Technologies GmbHflagshipStrategic or Co-development Partner · 5 November 2025NanoTemper Technologies GmbH announced the acquisition of Swedish startup Envue Technologies and the launch of its Dianthus α application on 2025-11-05/06. The acquisition integrates Envue's Nanofluidic Scattering Microscopy (NSM) technology into NanoTemper's biophysical analysis portfolio for drug discovery.
  • REACH Incubator Program (Silicon Valley)minorStrategic or Co-development Partner · 28 September 2022Envue selected to participate in REACH, a Silicon Valley-based incubator program designed to boost Nordic research-based tech projects and spin-outs with international ambitions. Program spans a year including a two-week trip to Silicon Valley in March 2023.
  • Chalmers University of Technology — Langhammer GroupcoreStrategic or Co-development PartnerEnvue was started as a spinout company from the Langhammer group at Chalmers University of Technology. The NSM method was developed by combining expertise in nano fabrication, nano optics and biophysics at Chalmers.

Scale indicators6 records

Recent moves1 record

Expansion highlights5 records

Envue Technologies competitors and assessment

Company assessment

Broad incumbents

  • Agilent Technologies: Analytical instrument and biocolumns vendor (SEC, CE, mass spec) serving biopharma characterization workflows. Comparable because it competes for analytical budget around protein and nucleic acid characterization in discovery and QC.
  • Cytiva (Danaher): Supplies bioprocess and analytical tools (ÄKTA, MicroCal ITC/DSF) used across biopharma discovery, developability, and QC. Comparable because it sells complementary label-free characterization workflows to the same biopharma buyer.
  • Malvern Panalytical: Established label-free particle-sizing incumbent via Zetasizer (DLS) and NanoSight (NTA). Comparable because these are the primary alternative label-free techniques that NSM positions against for biomolecule and nanoparticle characterization.
  • Wyatt Technology: Provides SEC-MALS, DLS (DynaPro), and field-flow fractionation for absolute molecular weight and size of biomolecules. Comparable because it competes for the same protein, nucleic acid, and aggregate characterization budgets in biopharma R&D and QC.
  • Thermo Fisher Scientific: Largest life-sciences tools vendor with mass spectrometry, microcalorimetry, and chromatography for protein characterization. Comparable as the broadest incumbent that could compete with or absorb NSM-style capabilities over time.
  • Bruker: Large analytical instrument vendor with mass spectrometry, AFM, and biophysical tools relevant to protein characterization. Comparable as a broad incumbent with the ability to bundle orthogonal label-free techniques alongside NSM-type offerings.

Emerging players

  • Fluidic Analytics: Developer of microfluidic label-free tools (Fluidity One) for protein interaction and sizing measurements. Comparable as a smaller player using microfluidics to deliver label-free biomolecule characterization in similar customer segments.
  • Unchained Labs: Sells benchtop biophysical tools for biologics developability (e.g., Uncle, Hunky, LUNATIC). Comparable because it targets the same biologics-formulation and developability workflows that NSM's mass/size and aggregation use cases address.

Direct peers

  • Refeyn: Refeyn commercializes mass photometry, the most established label-free single-molecule mass measurement technique. It is the closest direct competitor to Envue's NSM, serving the same biopharma discovery and academic customers with overlapping value propositions.

Others

  • NanoTemper Technologies: Acquirer of Envue and broader biophysical analysis incumbent offering DSF (Prometheus), MST, and now Dianthus α/NSM. Comparable because it sells to the same drug-discovery customers and increasingly bundles NSM into its portfolio.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Envue Technologies social profiles

Digital presence

Envue Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Envue Technologies leadership team

Management profile

Number of profiles

Profiles5 records

Envue Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Envue Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Envue Technologies

What does Envue Technologies do?

Envue Technologies develops, manufactures, and commercializes scientific instruments based on its proprietary Nanofluidic Scattering Microscopy (NSM) platform for the label-free characterization of biomolecules and nanoparticles. The company sells a modular Custom Instrument, an all-in-one EnvueR One benchtop instrument, and bundled nanofluidic chips with proprietary data analysis software, alongside fee-based sample analysis services for drug discovery and academic research customers.

Is Envue Technologies a public or private company?

Envue Technologies is a private company. It is classified as corporate owned and is currently acquired.

When was Envue Technologies founded?

Envue Technologies was founded in 2022. It employs 1 to 10 people.

Where is Envue Technologies based?

Envue Technologies is headquartered in Göteborg, Sweden, in the Europe region.

How does Envue Technologies make money?

Two revenue lines are on record. Instrument Sales are the primary driver. The others are sample Analysis Services.

Who are Envue Technologies's main competitors?

Broad incumbents on record are Agilent Technologies, Cytiva (Danaher), Malvern Panalytical, Wyatt Technology, Thermo Fisher Scientific and Bruker. Emerging players are Fluidic Analytics and Unchained Labs. Refeyn is listed as a direct peer. NanoTemper Technologies is listed as an others.

Does Envue Technologies have an API?

No public API is recorded for Envue Technologies.

What industry is Envue Technologies in?

Envue Technologies's product category is Biophysical Analysis Instruments. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Mass Spectrometry Web PortalNanoTemper Technologies GmbH. (11/5/25). "Press Release: NanoTemper Strengthens Biopharma Discovery Portfolio with Acquisition of Envue Technologies and Launch of Dianthus a". Munich & Gothenburg.NanoTemper Technologies GmbH has acquired Envue Technologies, a Swedish startup specializing in Nanofluidic Scattering Microscopy (NSM), and simultaneously launched Dianthus™ a application to strengthen its biopharma discovery portfolio. The acquisition enables single-molecule, label-free analysis capabilities, while Dianthus™ a adds Optical Unfolding and Slow Kinetics features to NanoTemper's existing Spectral Shift technology. These strategic milestones aim to help researchers make faster, more confident decisions in early-stage drug discovery across nucleic acid and protein modalities.Pulse 2.0NanoTemper Expands Drug Discovery Capabilities With Envue Acquisition And Launch Of Dianthus αNanoTemper Technologies has acquired Envue Technologies, a Swedish company specializing in Nanofluidic Scattering Microscopy, and simultaneously launched its new Dianthus α application to expand its biophysical analysis capabilities for early-stage biopharmaceutical research. The acquisition integrates Envue's label-free, single-molecule NSM technology with NanoTemper's existing Spectral Shift and TRIC technologies, enabling researchers to better characterize nucleic acid and protein therapeutics and assess hard-to-drug targets. NanoTemper will continue collaborating with industry and academic partners to streamline the process from data collection to therapeutic candidate selection.PR NewswireNanoTemper Strengthens Biopharma Discovery Portfolio with Acquisition of Envue Technologies and Launch of Dianthus™ αNanoTemper Technologies announced the acquisition of Envue Technologies and the launch of its Dianthus™ α application, expanding its biophysical analysis tools for drug discovery. The acquisition brings in Nanofluidic Scattering Microscopy (NSM) technology for label-free, single-molecule analysis, aiming to improve early-stage research in therapeutics.Chalmers VenturesEnvue is looking for a business developerEnvue Technologies AB, a Chalmers Ventures portfolio company, is seeking a business developer for its single-molecule microscopy startup. The role involves business development with established pharma contacts, and the position may lead to co-founder status. The company aims to bring its technology to market.